- Posted July 23, 2014 by
Melville, New York
Xarelto Lawsuits Start To Be Filed In The US Due To “Irreversible Bleeds”
Germany-based Bayer AG is facing its first lawsuits in the United States over Xarelto, which is among the company’s top-selling medications. According to Reuters, Xarelto made $1.3 billion in sales in 2013. Court records indicate that a Xarelto lawsuit was filed earlier this year on behalf of a Kentucky woman who alleged that she suffered severe internal bleeding after using the blood thinner. According to the complaint, the Kentucky woman was prescribed Xarelto in July 2012 to treat atrial fibrillation, and was hospitalized six months later with severe internal and gastrointestinal bleeding. The blood-thinning lawsuit contends that Johnson & Johnson should not have sold the medication and should have known Xarelto was associated with “irreversible bleeds.” The lawsuit against Johnson & Johnson and Bayer AG was filed on February 18, 2014, in the Pennsylvania Court of Common Pleas, Philadelphia County. (Stuntebeck v. Janssen Research & Development LLC et al, Case Number 140201754)
There is currently no reversing agent or antidote available to counteract Xarelto if internal bleeding is caused by the drug. Because there is a lack of options available if internal bleeding does occur, patients who are taking Xarelto and suffer internal bleeding are in serious danger of severe injury or even death.
Xarelto is a blood thinner medication, similar to Pradaxa and Coumadin (warfarin), used to reduce the risk of blood clots and strokes in patients with atrial fibrillation (irregular heart rhythms) not caused by heart valve problems. Patients taking the oral anticoagulant have reported serous side effects, including internal bleeding and hemorrhaging for which there is no antidote. Additionally, Xarelto came to market in November 2011 with a black box warning from the U.S. Food & Drug Administration (FDA) that sudden discontinuation of the medication increases a patient’s risk for heart attack or stroke.